@article{bylicki:hal-04016683,
TITLE = {Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018},
AUTHOR = {Bylicki, Olivier and Tomasini, Pascale and Radj, Gervais and Guisier, Florian and Monnet, Isabelle and Ricordel, Charles and Bigay-Game, Laurence and Geier, Margaux and Chouaid, Christos and Daniel, Catherine and Swalduz, Aurelie and Toffart, Anne-Claire and Doubre, Helene and Peloni, Jean-Michel and Moreau, Diane and Subtil, Fabien and Grellard, Jean-Michel and Castera, Marie and Clarisse, Benedicte and Martins-Lavinas, Pedro-Henrique and Decroisette, Chantal and Greillier, Laurent},
URL = {https://univ-rennes.hal.science/hal-04016683},
JOURNAL = {European Journal of Cancer},
PUBLISHER = {Elsevier},
VOLUME = {183},
PAGES = {38-48},
YEAR = {2023},
MONTH = Apr, DOI = {10.1016/j.ejca.2023.01.014},
KEYWORDS = {EGFR-mutation ; Immunotherapy ; Non-small cell lung cancer ; Resistance},
PDF = {https://univ-rennes.hal.science/hal-04016683/file/Bylicki%20et%20al.%20-%202023%20-%20Atezolizumab%20with%20or%20without%20bevacizumab%20and%20plati.pdf},
HAL_ID = {hal-04016683},
HAL_VERSION = {v1},
}